[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2008",
          "fs": "Dec 2008",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztCuUAI"
          },
          "Id": "a0P2P000002ztCuUAI",
          "Event_Date__c": "2008-12-01",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "Dec 2008",
          "Status_History__c": "a132P000000ApMxQAK"
        },
        "change": null
      }
    ],
    "dateString": "Dec 2008",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2009",
          "fs": "Feb 2009",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztCvUAI"
          },
          "Id": "a0P2P000002ztCvUAI",
          "Event_Date__c": "2009-02-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Feb 2009",
          "Status_History__c": "a132P000000ApNTQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "Recommended for funding with high priority on the Discretionary Community Supply List",
          "fs": "Recommended for funding with high priority on the Discretionary Community Supply List",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "fs": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2009-02.pdf \" target=\"_blank\">CaTSoP Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2009-02.pdf \" target=\"_blank\">CaTSoP Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2009",
          "fs": "Feb 2009",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Thursday 5 February 2009.",
          "fs": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Thursday 5 February 2009.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztCwUAI"
          },
          "Id": "a0P2P000002ztCwUAI",
          "Event_Date__c": "2009-02-05",
          "Event_Description__c": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Thursday 5 February 2009.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2009-02.pdf \" target=\"_blank\">CaTSoP Subcommittee minutes</a>",
          "Outcome__c": "High",
          "Summary__c": "Recommended for funding with high priority on the Discretionary Community Supply List",
          "Formatted_Date__c": "Feb 2009",
          "PTAC_Comments__c": "These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.",
          "Status_History__c": "a132P000000ApNsQAK"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "Recommended for funding with high priority on the Discretionary Community Supply List.",
          "fs": "Recommended for funding with high priority on the Discretionary Community Supply List.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2009",
          "fs": "May 2009",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztCxUAI"
          },
          "Id": "a0P2P000002ztCxUAI",
          "Event_Date__c": "2009-05-07",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2009.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "High",
          "Summary__c": "Recommended for funding with high priority on the Discretionary Community Supply List.",
          "Formatted_Date__c": "May 2009",
          "Status_History__c": "a132P000000ApQSQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Subcommittee noted that pegfilgrastim be included in a national preferred medicines list (PML) without need for further prioritisation:",
          "fs": "The Subcommittee noted that pegfilgrastim be included in a national preferred medicines list (PML) without need for further prioritisation:",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "No Formal Recommendation",
          "fs": "No Formal Recommendation",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">Hospital Pharmaceuticals Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">Hospital Pharmaceuticals Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Dec 2011",
          "fs": "Dec 2011",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 6 December 2011.",
          "fs": "Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 6 December 2011.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztCyUAI"
          },
          "Id": "a0P2P000002ztCyUAI",
          "Event_Date__c": "2011-12-06",
          "Event_Description__c": "Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 6 December 2011.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">Hospital Pharmaceuticals Subcommittee minutes</a>",
          "Outcome__c": "No Formal Recommendation",
          "Summary__c": "The Subcommittee noted that pegfilgrastim be included in a national preferred medicines list (PML) without need for further prioritisation:",
          "Formatted_Date__c": "Dec 2011",
          "Status_History__c": "a132P000000ApxDQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Subcommittee recommended that pegfilgrastim not be included in a national PML. The Subcommittee noted that individual patients would be able to have pegfilgrastim funded under NPPA, and considered that this would be appropriate.",
          "fs": "The Subcommittee recommended that pegfilgrastim not be included in a national PML. The Subcommittee noted that individual patients would be able to have pegfilgrastim funded under NPPA, and considered that this would be appropriate.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Not recommended for inclusion (HML)",
          "fs": "Not recommended for inclusion (HML)",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">Haematology Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">Haematology Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2012",
          "fs": "Aug 2012",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Haematology Subcommittee at meeting Monday 6 August 2012.",
          "fs": "Clinical advice received from Haematology Subcommittee at meeting Monday 6 August 2012.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztCzUAI"
          },
          "Id": "a0P2P000002ztCzUAI",
          "Event_Date__c": "2012-08-06",
          "Event_Description__c": "Clinical advice received from Haematology Subcommittee at meeting Monday 6 August 2012.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">Haematology Subcommittee minutes</a>",
          "Outcome__c": "Not recommended for inclusion (HML)",
          "Summary__c": "The Subcommittee recommended that pegfilgrastim not be included in a national PML. The Subcommittee noted that individual patients would be able to have pegfilgrastim funded under NPPA, and considered that this would be appropriate.",
          "Formatted_Date__c": "Aug 2012",
          "Status_History__c": "a132P000000Aq7JQAS"
        },
        "change": null
      },
      {
        "Summary": {
          "s": "The Subcommittee recommended that pegfilgrastim should be listed on the PML only if cost neutral to filgrastim.",
          "fs": "The Subcommittee recommended that pegfilgrastim should be listed on the PML only if cost neutral to filgrastim.",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Cost Neutral",
          "fs": "Cost Neutral",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">CaTSoP Subcommittee minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">CaTSoP Subcommittee minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2012",
          "fs": "Oct 2012",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 October 2012.",
          "fs": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 October 2012.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztD0UAI"
          },
          "Id": "a0P2P000002ztD0UAI",
          "Event_Date__c": "2012-10-05",
          "Event_Description__c": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 October 2012.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-blood-and-blood-forming-organs-group-minutes-2013-02.pdf \" target=\"_blank\">CaTSoP Subcommittee minutes</a>",
          "Outcome__c": "Cost Neutral",
          "Summary__c": "The Subcommittee recommended that pegfilgrastim should be listed on the PML only if cost neutral to filgrastim.",
          "Formatted_Date__c": "Oct 2012",
          "Status_History__c": "a132P000000AqAFQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Cost Neutral",
          "fs": "Cost Neutral",
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf \" target=\"_blank\">PTAC minutes</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf \" target=\"_blank\">PTAC minutes</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2013",
          "fs": "Feb 2013",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 February 2013.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 February 2013.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztD1UAI"
          },
          "Id": "a0P2P000002ztD1UAI",
          "Event_Date__c": "2013-02-14",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 February 2013.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf \" target=\"_blank\">PTAC minutes</a>",
          "Outcome__c": "Cost Neutral",
          "Formatted_Date__c": "Feb 2013",
          "Status_History__c": "a132P000000AqIhQAK"
        },
        "change": null
      }
    ],
    "dateString": "Feb 2009",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2013",
          "fs": "Apr 2013",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztD2UAI"
          },
          "Id": "a0P2P000002ztD2UAI",
          "Event_Date__c": "2013-04-12",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Formatted_Date__c": "Apr 2013",
          "Status_History__c": "a132P000000AqNgQAK"
        },
        "change": null
      }
    ],
    "dateString": "Apr 2013",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/news/item/tocilizumab-and-pegfilgrastim\" target=\"_blank\">Consultation letter</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/news/item/tocilizumab-and-pegfilgrastim\" target=\"_blank\">Consultation letter</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2013",
          "fs": "Apr 2013",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztD3UAI"
          },
          "Id": "a0P2P000002ztD3UAI",
          "Event_Date__c": "2013-04-29",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/news/item/tocilizumab-and-pegfilgrastim\" target=\"_blank\">Consultation letter</a>",
          "Formatted_Date__c": "Apr 2013",
          "Status_History__c": "a132P000000AqO1QAK"
        },
        "change": null
      }
    ],
    "dateString": "Apr 2013",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<a href=\"https://www.pharmac.govt.nz/news/item/pegfilgrastim-and-tocilizumab\" target=\"_blank\">Notification letter</a>",
          "fs": "<a href=\"https://www.pharmac.govt.nz/news/item/pegfilgrastim-and-tocilizumab\" target=\"_blank\">Notification letter</a>",
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2013",
          "fs": "May 2013",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been Approved.",
          "fs": "The funding application has been Approved.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000002ztD4UAI"
          },
          "Id": "a0P2P000002ztD4UAI",
          "Event_Date__c": "2013-05-01",
          "Event_Description__c": "The funding application has been Approved.",
          "Stage__c": "Decision",
          "Links__c": "<a href=\"https://www.pharmac.govt.nz/news/item/pegfilgrastim-and-tocilizumab\" target=\"_blank\">Notification letter</a>",
          "Formatted_Date__c": "May 2013",
          "Status_History__c": "a132P000000AqONQA0"
        },
        "change": null
      }
    ],
    "dateString": "May 2013",
    "collapsed": false,
    "checked": true
  }
]